Back to today’s briefing

Story perspectives

ClearNote's Cancer Test Selected for Landmark Study

1/11/2025

41 9

Summary

Story summary

ClearNote Health's groundbreaking Avantect multi-cancer detection test has been chosen for the National Cancer Institute's Vanguard Study, aiming to assess non-invasive blood tests for early cancer detection in 24,000 participants. This pivotal research could revolutionize early diagnosis, enhancing survival rates and showcasing the transformative potential of ClearNote's innovative technology in the fight against cancer.

1 of 1

Story summary

ClearNote Health's groundbreaking Avantect multi-cancer detection test has been chosen for the National Cancer Institute's Vanguard Study, aiming to assess non-invasive blood tests for early cancer detection in 24,000 participants. This pivotal research could revolutionize early diagnosis, enhancing survival rates and showcasing the transformative potential of ClearNote's innovative technology in the fight against cancer.